Today, the @US_FDA is providing health care providers with an update on the potential risks of over-inflation, acute pancreatitis, and deaths in patients with Orbera and ReShape intragastric balloons used for weight loss.pic.twitter.com/T38tdu7r06

Today, the @US_FDA is providing health care providers with an update on the potential risks of over-inflation, acute pancreatitis, and deaths in patients with Orbera and ReShape intragastric balloons used for weight loss. pic.twitter.com/T38tdu7r06
Source: Food and Drug Adminstration (FDA): CDRHNew - Category: Medical Devices Authors: Source Type: news